Avitide Raises Funds For “On-Demand” Affinity Processing
This article was originally published in Start Up
In early August, Avitide raised a $7.6 million Series C round that it says will provide sufficient funds for it to commercialize its high-yield process for purifying just about any biological product, a service it will offer to its pharma partners.
You may also be interested in...
Relay launched with $57m to develop its novel technology platform for drug discovery based on protein motion with an initial focus on therapies for genetically defined cancers.
Outsourcing is not just for mundane pharma services anymore. Increasingly, drugmakers are contracting for specialized R&D assistance they expect to provide strategic as well as tactical advantages.
Like other companies investigating entirely new ways of treating bacterial infections, biotech start-up Spero is increasingly aware that novel antibiotics may need to travel new clinical and regulatory pathways to market.